⌘K
Loading ticker…
As of 2026-08-24, Apogee Therapeutics, Inc. Common Stock (APGE) has a 3-month relative strength percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 84. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 0.1%, relative volume 0.90×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
APGE is in a stage 2 uptrend, week 11. Currently in a 11-day base; basing ADR 0.1% (broad 2.7%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 4.2% / 50.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
APGE is held by 28 ETFs as of May 2026. Top owner: SCHA at 0.09% weight, $21M notional. Top 3 carry $49M.
Held by 62 ETFs · $596M across latest filings · largest weight 2.93% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.09% | $21M | +0.01 pp |
| VTWO | 0.11% | $19M | +0.02 pp |
| VHTVanguard Health Care ETF | 0.05% | $9M | +0.02 pp |
| SBIO | 2.93% | $5M | +0.45 pp |
| VTWG | 0.20% | $3M | +0.03 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.01% |
| $3M |
| — |
| VFMO | 0.10% | $2M | — |
| FSCC | 0.50% | $1M | +0.03 pp |
| ESML | 0.06% | $1M | — |
| ONEQ | 0.01% | $1M | — |
Showing 10 of 28 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APGE Jan avg: -0.67% median: -8.70% win: 33% σ: 17.95% n: 3 2023-07-17 → 2026-07-31 | APGE Feb avg: -4.40% median: 3.94% win: 67% σ: 17.03% n: 3 2023-07-17 → 2026-07-31 | APGE Mar avg: 43.30% median: 20.24% win: 100% σ: 41.17% n: 3 2023-07-17 → 2026-07-31 | APGE Apr avg: -6.92% median: -1.52% win: 33% σ: 15.41% n: 3 2023-07-17 → 2026-07-31 | APGE May avg: -5.61% median: -6.65% win: 0% σ: 4.28% n: 3 2023-07-17 → 2026-07-31 | APGE Jun avg: 22.11% median: 18.53% win: 67% σ: 37.81% n: 3 2023-07-17 → 2026-07-31 | APGE Jul avg: 3.42% median: 0.91% win: 75% σ: 14.85% n: 4 2023-07-17 → 2026-07-31 | APGE Aug avg: 2.44% median: 5.07% win: 67% σ: 6.48% n: 3 2023-07-17 → 2026-07-31 (current) | APGE Sep avg: 5.63% median: 9.24% win: 67% σ: 11.41% n: 3 2023-07-17 → 2026-07-31 | APGE Oct avg: 3.90% median: -11.41% win: 33% σ: 33.61% n: 3 2023-07-17 → 2026-07-31 | APGE Nov avg: 9.17% median: 13.56% win: 67% σ: 20.56% n: 3 2023-07-17 → 2026-07-31 | APGE Dec avg: 16.14% median: 4.88% win: 100% σ: 23.55% n: 3 2023-07-17 → 2026-07-31 |